在澳大利亚和其他司法管辖区，医用大麻的使用正在增加，但人们对医用大麻对认知功能的影响知之甚少。非医用（“娱乐”）大麻的研究结果可能不适用于使用处方医用大麻来管理健康状况的患者。在这项半自然主义、开放标签试验中，患有各种健康状况的患者参加了一次实验室会议他们按照药房标签上的说明自行服用标准剂量的处方医用大麻。我们在医用大麻自我给药之前和之后（CANTAB：3小时；Druid：3和5.5小时）使用剑桥神经心理学测试自动电池（CANTAB）和Druid应用程序（应用程序）评估认知表现。我们还使用一系列 0-10 厘米视觉模拟量表（“吸毒”、“镇静”、“放松”、“舒适”）评估了医用大麻自我给药之前和之后（1、2 和 4 小时）的主观药物效应。 、“焦虑”和“自信”）。使用线性固定效应模型对数据进行分析。参与者（N = 40；22 名女性）服用了一系列产品，包括口服油（n = 23）和汽化花（n = 17）。参与者的平均（标准差 [SD]）年龄为 41.38（12.66）岁，使用医用大麻的平均（SD）为 10.18（8.73）个月。慢性非癌症疼痛是使用医用大麻的最常见适应症（n = 20），其次是睡眠障碍（n = 18）和焦虑（n = 11）。参与者服用的 delta-9-四氢大麻酚 (THC)/大麻二酚 (CBD) 的平均 (SD) 剂量为 9.61 (8.52) mg/9.15 (10.11) mg，使用油的参与者为 37.00 (24.53) mg/0.38 (1.58) ) 毫克分别在那些蒸发花的人中。随着时间的推移，参与者在 CANTAB 多任务测试和快速视觉信息处理测试中的表现不断提高（p 值均<0.001）。随着时间的推移，认知表现指标的所有其他变化均不显着 (p > 0.05)。与油相比，花的蒸发与“石头”和“镇静”的主观感觉明显更强相关（p < 0.001）。这些研究结果表明，处方药用大麻可能对患有慢性疾病的患者的认知功能产生最小的急性影响，尽管需要更大规模的对照试验。© 2023。作者。

Medical cannabis use is increasing in Australia and other jurisdictions, yet little is known about the effects of medical cannabis on cognitive function. Findings from studies of non-medical ('recreational') cannabis may not be applicable to patients using prescribed medical cannabis to manage a health condition.In this semi-naturalistic, open-label trial, patients with various health conditions attended a single laboratory session in which they self-administered a standard dose of prescribed medical cannabis as per instructions on the pharmacy label. We assessed cognitive performance using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and Druid application (app) prior to and following (CANTAB: + 3 h; Druid: + 3 and 5.5 h) medical cannabis self-administration. We also assessed subjective drug effects prior to and following (1, 2 and 4 h) medical cannabis self-administration using a range of 0-10 cm visual analogue scales ('stoned', 'sedated', 'relaxed', 'comfortable', 'anxious' and 'confident'). Data were analyzed using linear fixed-effect models.Participants (N = 40; 22 females) were prescribed a range of products including orally administered oils (n = 23) and flower for vaporization (n = 17). Participants had a mean (standard deviation [SD]) age of 41.38 (12.66) years and had been using medical cannabis for a mean (SD) of 10.18 (8.73) months. Chronic non-cancer pain was the most common indication for medical cannabis use (n = 20), followed by sleep disorder (n = 18) and anxiety (n = 11). The mean (SD) delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) dose administered by participants was 9.61 (8.52) mg/9.15 (10.11) mg among those using an oil, and 37.00 (24.53) mg/0.38 (1.58) mg among those who vaporized flower, respectively. Participants' performance improved over time on the CANTAB Multitasking Test and Rapid Visual Information Processing test (both p-values <0.001). All other changes in cognitive performance measures over time were non-significant (p > 0.05). Vaporization of flower was associated with significantly stronger subjective feelings of 'stoned' and 'sedated' relative to oils (both p < 0.001).These findings suggest that prescribed medical cannabis may have minimal acute impact on cognitive function among patients with chronic health conditions, although larger and controlled trials are needed.© 2023. The Author(s).